Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 29;10(3):e0050322.
doi: 10.1128/spectrum.00503-22. Epub 2022 May 23.

Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study

Affiliations

Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study

Angsana Phuphuakrat et al. Microbiol Spectr. .

Abstract

Determination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is important in guiding the infection control and differentiating between reinfection and persistent viral RNA. Although viral culture is the gold standard to determine viral infectivity, the method is not practical. We studied the kinetics of SARS-CoV-2 total RNAs and subgenomic RNAs (sgRNAs) and their potential role as surrogate markers of viral infectivity. The kinetics of SARS-CoV-2 sgRNAs compared to those of the culture and total RNA shedding in a prospective cohort of patients diagnosed with coronavirus disease 2019 (COVID-19) were investigated. A total of 260 nasopharyngeal swabs from 36 patients were collected every other day after entering the study until the day of viral total RNA clearance, as measured by reverse transcription PCR (RT-PCR). Time to cessation of viral shedding was in order from shortest to longest: by viral culture, sgRNA RT-PCR, and total RNA RT-PCR. The median time (interquartile range) to negativity of viral culture, subgenomic N transcript, and N gene were 7 (5 to 9), 11 (9 to 16), and 18 (13 to 21) days, respectively (P < 0.001). Further analysis identified the receipt of steroid as the factors associated with longer duration of viral infectivity (hazard ratio, 3.28; 95% confidence interval, 1.02 to 10.61; P = 0.047). We propose the potential role of the detection of SARS-CoV-2 subgenomic RNA as the surrogate marker of viral infectivity. Patients with negative subgenomic N RNA RT-PCR could be considered for ending isolation. IMPORTANCE Our study, combined with existing evidence, suggests the feasibility of the use of subgenomic RNA RT-PCR as a surrogate marker for SARS-CoV-2 infectivity. The kinetics of SARS-CoV-2 subgenomic RNA should be further investigated in immunocompromised patients.

Keywords: COVID-19; SARS-CoV-2; infectivity; subgenomic RNA; viral shedding.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Comparison of cycle threshold (Ct) values of ORF1ab (A), total N (B), subgenomic S (C), and subgenomic N (D) versus duration of illness (DOI) in a prospective cohort of COVID-19 patients. Blue and red circles represent samples with isolable and nonisolable viable viruses, respectively. Linear regression equation of each panel is shown in each panel. CN, culture negativity (nonisolable viable virus = 1; isolable viable virus = 0).
FIG 2
FIG 2
Time to cessation of SARS-CoV-2 viral shedding. Black, blue, and red represent isolable virus, total N RNA, and subgenomic N RNA, respectively.

Similar articles

Cited by

References

    1. World Health Organization. 2020. WHO Director-General's opening remarks at the media briefing on COVID-19—11 March 2020. World Health Organization, Geneva, Switzerland. https://www.who.int/director-general/speeches/detail/who-director-genera.... Accessed November 10, 2021.
    1. Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ, Loeb M, Patel R, El Alayli A, Altayar O, Patel P, Falck-Ytter Y, Lavergne V, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. 2021. The Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. Clin Infect Dis ciab048. doi:10.1093/cid/ciab048. - DOI - PMC - PubMed
    1. Tang YW, Schmitz JE, Persing DH, Stratton CW. 2020. Laboratory diagnosis of COVID-19: current issues and challenges. J Clin Microbiol 58:e00512-20. doi:10.1128/JCM.00512-20. - DOI - PMC - PubMed
    1. Kim MC, Cui C, Shin KR, Bae JY, Kweon OJ, Lee MK, Choi SH, Jung SY, Park MS, Chung JW. 2021. Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19. N Engl J Med 384:671–673. doi:10.1056/NEJMc2027040. - DOI - PMC - PubMed
    1. Tarhini H, Recoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P, Lucet JC, Rioux C, Bouzid D, Lebourgeois S, Descamps D, Yazdanpanah Y, Le Hingrat Q, Lescure FX, Visseaux B. 2021. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis 223:1522–1527. doi:10.1093/infdis/jiab075. - DOI - PMC - PubMed

Publication types